Navigation Links
Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
Date:11/20/2008

TROMSO, Norway, November 20 /PRNewswire/ -- The Scandinavian-based drug development company Lytix Biopharma has announced results of studies on its lead antimicrobial candidate LTX-109. Presented at ICAAC in Washington, DC, the studies showed that the novel lytic peptidomimetic has an ultra-rapid bacteriocidal effect, significantly better towards killing Staphylococcus aureus and Streptococcus pyogenes than marketed gold standard drugs. In addition to this it has proven effective against a wide range of 110 European Pseudomonas aeruginosa clinical isolates, a problrmatic Gram (-) bacterium.

According to Lytix Biopharma spokesperson Anders Fugelli, these are important studies: "The fact that LTX-109 is effective against a broad range of pathogens highlights its potential utility as a truly novel broad spectrum antimicrobial drug. Indeed it is so effective, that although the initial formulation is for the treatment of skin infections, we could now consider it for other indications such as skin and nail fungal infections, acne and oropharyngeal candidaisis. We are now in the final stages of preclinical development and look forward to taking LtX-109 into the clinic in during the second half of 2009."

LTX-109 is a novel synthetic antimicrobial pepitidomimetic (SAMP) drug with a rapid bactericidal mode of action that can effectively synthesized in scalable, low-cost chemical reactor systems.

About Lytix Biopharma AS

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments. Lytix was established in 2003 to commercialise world-class research in the field of lytic peptides spun out by the founding scientists working in the University Hospital and University of Tromso in Norway.

Operating out of a main office located in Tromso and through our continued collaboration with the University o
'/>"/>

SOURCE Lytix Biopharma AS
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
6. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
7. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
8. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
9. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 ... today announced a partnership to expand awareness of proper ... the CFChef Shares program. CFChef Shares will run from ... AbbVie,s CFChef program – an online resource for CF ... a healthy diet by submitting recipes to the ...
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced ... report its second quarter 2014 financial results on Monday, ... J. Joseph Kim and CFO Peter ... corporate update, and participate in a live Q&A with ... VGX-3100, Inovio,s immune therapy targeting pre-cancers and cancers associated ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/1/2014)... The European gas chromatography systems report defines and segments the ... The gas chromatography systems market in Europe is valued at ... around $247.6 million by 2018, at a CAGR of 5.3% ... the European gas chromatography systems market, to get an idea ... of the segmentation of gas chromatography systems market in the ...
(Date:8/1/2014)... 2014 The North America Sports Drink Market ... America, with analysis and forecast of revenue. The Sports Drink ... $5,021.9 million in 2012 to $6,243 million by 2018, at ... through the TOC of the North America Sports Drink market ... This also provides a glimpse of the segmentation in the ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Carole B. Lewis, PT, DPT, ... recipient of the Excellence in Rehabilitation of Aging Persons ... acknowledge outstanding contributions in the field of rehabilitation. The ... or patient care, or publications that may include scholarly ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , ... to be recognized as a 2014 Best of Home Care ... care providers who rank in the top 50th percentile in ... interviews conducted by Home Care Pulse. , “The Best ... the best of the best!” says Home Care Pulse Founder ...
(Date:8/1/2014)... 01, 2014 With fast food restaurants on ... convenience of processed, microwavable dinners, it is no wonder that ... offer patients a mere quick fix for shedding this dangerous ... part of the country, get slimmer and healthier for the ... the tools and education on how to avoid obesity ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3
... cancer that is being developed is the use of ... normal cells unharmed. These viruses are known as virotherapeutics. ... Jennerex Biotherapeutics, San Francisco, have described the development of ... and rabbits. , After selecting a highly potent strain ...
... in cancer incidence and mortality are well documented. ... is a factor in cancer disparities, other factors ... genetics, hormonal status, lifestyle and behavior, screening policies, ... response to therapy, and post-therapeutic surveillance. , ...
... used to cut down on bleeding during cardiac surgery , , ... Drug Administration on Thursday said it will review the safety ... trial was stopped early due to an increase in deaths ... first approved by the FDA in 1993, is typically used ...
... Oct. 25 /PRNewswire-FirstCall/ - SXC Health Solutions Inc.,(NASDAQ: ... Glenn, Chairman and,Chief Executive Officer, will host a conference ... to discuss the Company,s fiscal 2007 third quarter,financial results. ... at 6:00 a.m. ET that same day. All ...
... During the Second Fiscal ... Quarter ... Reiterates Fiscal 2008 Guidance, MOUNTAIN VIEW, Calif., Oct. 25 Pharsight,Corporation (OTC ... clinical drug development, today,announced financial results for its second quarter of fiscal 2008, ...
... with Osiris on a Phase II Trial to Evaluate ... , New York, NY October 25, ... a partnership with Osiris Therapeutics, Inc. (NASDAQ:OSIR) to support ... cell therapy product, to preserve and regenerate insulin-producing cells ...
Cached Medicine News:Health News:FDA to Review Clotting Drug After Trial Suggests Death Risk 2Health News:FDA to Review Clotting Drug After Trial Suggests Death Risk 3Health News:FDA to Review Clotting Drug After Trial Suggests Death Risk 4Health News:SXC Health Solutions to Host Fiscal 2007 Third Quarter Financial Results Conference Call 2Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 2Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 3Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 4Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 5Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 6Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 7Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 8Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 9Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 10Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 11Health News:Pharsight Achieves $7.3 Million in Quarterly Revenue 12Health News:JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes 2
... Complete includes the nutrients used in the ... Antioxidant Supplement Trial (LAST), which suggested no ... in a one year period. Macula Complete ... in peer-reviewed studies to support the mitochondria, ...
... Soft Gel Lutein patented formula is based ... PreserVision® AREDS formula, with the beta-carotene substituted ... is a carotenoid found in dark leafy ... highly concentrated in the macula, the part ...
... & Lomb PreserVision® AREDS formula is the ... supplement clinically proven effective in the 10-year ... Eye Disease Study (AREDS). , PreserVision® AREDS ... supplement with the antioxidant vitamins A, C, ...
... scientific formulation that provides the foundation ... basic eye-specific nutritional support. All ingredients ... standards, when applicable. ScienceBased Health formulations ... maximum bioavailability, and are free of ...
Medicine Products: